Skip to main content

Table 3 Sensitivity analysis of linear mixed model results for the MCI and dementia groups for plasma TG/HDL, ApoA1, and CSF ApoA1 using imputed data

From: Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease

 

MCI group

Dementia group

Effect

Slope (95% CI)

p-value

Slope (95% CI)

p-value

MMSE

 CSF ApoA1

0.219

(0.068, 0.370)

0.005

 − 0.407

(− 1.157, 0.344)

0.29

 Plasma ApoA1

 − 0.492

(− 0.717, − 0.266)

 < 0.001

 − 1.207

(− 2.537, 0.123)

0.075

 TG/HDL

 − 0.165

(− 0.275, − 0.054)

0.004

 − 0.247

(− 0.950, 0.455)

0.49

CDR-SB

 CSF ApoA1

 − 0.065

(− 0.174, 0.044)

0.24

 − 0.015

(− 0.446, 0.417)

0.95

 Plasma ApoA1

0.173

(0.006, 0.340)

0.043

0.522

(− 0.246, 1.290)

0.18

 TG/HDL

0.152

(0.070, 0.234)

 < 0.001

0.402

(− 0.002, 0.807)

0.051

LM

 CSF ApoA1

0.039

(− 0.086, 0.165)

0.54

0.118

(− 0.176, 0.412)

0.43

 Plasma ApoA1

 − 0.280

(− 0.467, − 0.094)

0.003

 − 0.344

(− 0.862, 0.174)

0.19

 TG/HDL

 − 0.010

(− 0.101, 0.082)

0.83

0.134

(− 0.147, 0.415)

0.35

  1. Linear mixed effect models
  2. MMSE Mini-Mental Status Exam score, CDR-SB Clinical Dementia Rating Scale–Sum of Boxes score, LM Logical memory delayed recall score